Healios K.K.
https://www.healios.co.jp/en/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Healios K.K.
Asia Deal Watch: Rona Takes On Sanofi’s siRNA Platform
Rona hopes technology acquired from Sanofi will enhance its RNA capabilities in liver and non-liver indications. NeuroFront gets Greater China and Singapore rights to Novaremed’s neuropathic pain drug.
Healios, Athersys Confident Despite Missed Japan Stroke Endpoint
A missed primary endpoint in new top-line results from a Japanese trial with the stem cell therapy for stroke MultiStem hits Athersys and Japanese partner hard, casting a shadow over ongoing studies.
Deal Watch: Private Equity-Backed Covis Bids To Buy Troubled AMAG
Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.
Coronavirus Update: Will Moderna Really Demand Premium Price For COVID Vaccine?
There are reports that the US biotech is considering pricing its as-yet-unapproved mRNA-1273 at $25-30 a dose, a price which would double as both a prime and boost dose would be administered.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Healios Riken, SighRegen K.K.
- Healios N.A. Inc.
- Organoid Neogenesis Laboratory Inc.